Photos: 

Some evaluation reports are public and can be downloaded from this website, while others are restricted to MSF users and can only be accessed via Tukul. This limitation is mainly due to the sensitive nature of the operational contexts and the resulting content. However, there are internal discussions about making all evaluation reports publicly searchable. If you are an MSF association member, reports are made available on various associate platforms such as www.insideOCB.com.

Country/Region

In 2015, MSF operations and medical directors recognised antibiotic resistance (ABR) as a priority and called for the elaboration of an intersectional roadmap to tackle ABR in MSF projects. The MSF ABR Task Force was consolidated in 2017 with joint medical and operational governance.

These case study reports were produced at the request of MSF-OCBA, under the management of the Vienna Evaluation Unit. They were prepared independently by the respective authors.
09/09/2019

MSF has received UNITAID grants since 2013. For several financial, operational and opportunistic reasons, the opportunity and adequacy of receiving funds from UNITAID was questioned by the MSF medical and operational directors. In October 2014 the MedOp platform took a decision not to seek any further UNITAID funding for a one-year period-ending in October 2015.

This evaluation was conducted by Nicole Henze on behalf of the Stockholm Evaluation Unit of MSF. Finalised in November 2015. This publication was produced at the request of MSF MedOp, under the management of the Stockholm Evaluation Unit. It was prepared independently by Nicole Henze.
30/12/2015

The example of Shishelweni demonstrates that in the context of high prevalence of HIV/TB infections and limited resources available decentralisation of HIV and TB care from regional and district hospitals to primary health care clinics and community level is the way to improve access, coverage, effectiveness and efficiency of service delivery. It also improves satisfaction and acceptance of health service providers, direct beneficiaries and the wider community.

Mzia Turashvili
01/12/2013

This report summarises the key lessons learned from MSF's cholera interventions in Zambia 2004, 2006, 2008, 2010 (OCBA), Guinea Bissau 2005-2008 (OCBA), Juba 2006 (OCBA), Haiti 2010-2011 (OCBA), Angola 2006 (OCB, OCA, OCBA), Zimbabwe 2009 (OCB, OCA, OCBA)

M Iscla
09/05/2012

MSF-OCA has been addressing a highly relevant issue, TB and DR-TB in Uzbekistan. A steady decrease of the notification and the mortality rates has been indicating a good outcome of the TB DOTS programme. MSF is highly appreciated by the MOH of Uzbekistan as one of the main partners in TB control and the first one who started the diagnosis and treatment of DR-TB. The current model of comprehensive TB care was estimated as the most appropriate approach for this low-income country with high TB/MDR-TB burden. It could be successfully expanded to elsewhere in the region.

Kai Blöndal and Oscar Bernal
25/02/2011

Reviewed Interventions This chapter provides an overview of the contexts and MSF interventions of all the reviewed interventions (DRC, Cameroun, Djibouti, Iraq, South Africa and Pakistan).

Alena Koscalova, Elena Lucchi
16/12/2010

The purpose of this evaluation was to review the experience in needs assessment and response to displacement in open settings. For the evaluation process, six interventions were reviewed: MSF Operational Centre Geneva (OCG) interventions in the Democratic Republic of Congo (DRC) (Haut-Uélé), Djibouti, Cameroon and Iraq; Operational Centre Brussels (OCB) interventions in South Africa and Pakistan; and partial review of Operational Centre Paris (OCP) experience in Pakistan.

Alena Koscalova and Elena Lucchi
01/06/2010

The Bosnia programme was one of the largest programmes MSF has implemented so far, and it was the first major operation MSF executed in an European environment. There was a widely shared view that the programme had gone “out of control”. As a result, many within MSF considered drug distribution in general as being beyond the scope of MSF. The dominance of drug distribution in the programme was perceived to be in contradiction with the medical identity of MSF.

Van de Putte, B. and Maslesa, L.
01/04/1998